# Ajax Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ajax-health

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.ajaxhealth.com
- Total disclosed funding: $205M
- Latest round: Series C (Apr 11, 2019)
- Investors on record: 6

## About

Ajax Health LLC is a medical technology company dedicated to developing innovative solutions that enhance patient outcomes and streamline healthcare delivery. Their focus on advanced medical devices supports diverse clinical needs in healthcare.Founded in 2017 in Menlo Park, US, Ajax Health LLC develops medical technology solutions to improve healthcare delivery. The company has undergone strategic pivots, focusing on innovative product development. Duke Rohlen, the founder and CEO, leads the company, which has successfully raised USD 100.00 mn in total funding across 4 deals, with the latest funding from HealthQuest Capital and Polaris Partners on September 30, 2019.Ajax Health specializes in creating advanced medical devices and systems aimed at enhancing patient care and operational efficiency. Their product portfolio predominantly serves the cardiovascular and surgical applications sectors, targeting healthcare providers, hospitals, and specialty clinics in North America and Europe. The solutions are designed to improve access to care and address critical challenges in the medtech industry.Ajax Health generates revenue through direct sales and B2B partnerships with healthcare providers and distributors. The company focuses on supplying innovative medical devices to hospitals and specialty clinics, utilizing established contracts that may include bulk purchasing agreements or subscription services for ongoing support. Their flagship products, integral to their revenue generation, are positioned competitively to reflect the value delivered to healthcare institutions.Ajax Health plans to utilize the recent funding of USD 100.00 mn raised on September 30, 2019, to support the design and launch of new products aimed at enhancing healthcare outcomes. The company is strategically targeting expansion into new geographic regions, particularly in Europe, by 2023. This growth initiative will bolster their market presence and address the critical needs in medical technology.

## Funding rounds

- Series C, Apr 11, 2019, $85M — Polaris Partners, Aisling Capital, HealthQuest Capital
- Series B, Jul 9, 2018, $120M — KKR, Polaris Partners, Aisling Capital, WTI, ICONIQ Capital, HealthQuest Capital

## Investors

- KKR (https://capitalatlas.ai/funds/kkr) — Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B, Series C
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B, Series C
- WTI — Series B
- ICONIQ Capital (https://capitalatlas.ai/funds/iconiq-capital) — Series B
- HealthQuest Capital (https://capitalatlas.ai/funds/healthquest-capital) — Series B, Series C